Mission BioCapital

Our goal is to help entrepreneurs turn their own ideas and visions into successful companies with fundraising and networking guidance. As a results-driven organization, we are constantly looking for ambitious and visionary partners with the drive and flexibility to take their company to the next level.

Headquartered in Silicon Valley, H7 BioCapital is a global venture platform that supports the transformational growth of healthcare companies through its influential venture capital financing, global accelerator program, venture club, VC class, webinars, conferences and other strategic events, and connect them with investors, scientists, physicians, corporate partners and other industrial professionals to jointly build a resource - rich healthcare innovation ecosystem. H7 BioCapital consists of three parts of organizations: H7 Accelerator, H7 Venture, and H7 Café to support the transformational growth of healthcare by striving to be transformational itself. Need a boost with your healthcare startup? Let H7 be your support - Health, Heal, Happiness, Hope, Humanity, Home and Holistic! H7 Accelerator 3-month-long cohort-based healthcare accelerator program providing mentorship, funding and other support to early-stage biotech, medtech and device startups along with a lifelong network for these leaders and innovators. H7 Venture Investment platform providing early stage funding support to healthcare startups that are believed to have a long-term growth potential. H7 Café A high-quality startup community that supports the growth of healthcare entrepreneurs by frequent events such as networking, educational workshop, private deal flow meetings and other programs to connect the corporate, scientists, investor and founder ecosystem.

Cambrian Biopharma, a multi-asset longevity biotech, is building the medicines that will redefine healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. By partnering with leading academic institutions and biotech entrepreneurs all over the world, we are advancing a diversified pipeline of novel therapeutics, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve overall quality of life as we age. Cambrian is a Distributed Development Company (or DisCo) which combines the advantages of a venture capital firm and a big pharmaceutical company, with the nimbleness of a biotech startup. Cambrian’s sourcing and development engine allows us to identify promising science, deploy capital and teams of drug development experts, and provide stewardship to advance new medicines. By leveraging established expertise and repeatable functional models, we achieve vast efficiencies in execution speed and resource utilization. To date, we have 14 novel therapeutics in development, and having closed a Series C financing round in October 2021 which raised $100 million, we plan to expand the number of programs. Further, we expect to initiate clinical trials for three programs in the next 18 months.

We are a European family office owned fund; we understand biosciences and medical technologies better than anyone else in the Private Equity and Venture Capital ecosystem. The capital of this fund has been generated by the family office's active bioscience investments across Europe, USA, and the APAC region since 1995. We understand the intricacies of commercializing bioscience discoveries. We also acknowledge that bioscience venture leadership requires deep courage - from founders and the investors that back them. What we look for We operate globally and only review investment opportunities submitted to us by our partner investment banks across the globe. If we believe in the transformative power of the discovery and the founder's ambition, this will suffice for us to determine the venture's potential. Our approach Upon receipt of a proposal from our investment bank partners, we will analyze the proposed deal, meet with the venture founders, and understand their vision. We will propose a deal size and structure. Execute a letter of intent and perform appropriate due diligence, negotiate, and execute a mutually acceptable binding contract. Release the required funding, close the transaction and work together to grow the business.

We support the development of novel medicines that address significant unmet medical needs. As co-investors, you will find us straight forward, transparent, long term oriented and asking “is this the right thing to do for the company” at every step of our decision making. Investment strategy and approach Our investment and portfolio construction strategy builds on lessons learned and approaches perfected during the 15 years the founding team worked together. We invest in companies that are about to enter the most value-generating phase of drug development i.e. clinical stage. Our capital helps answer the question “Is there a drug that works here?” We can lead, co-lead or follow. We (almost) always take Board seats in companies we invest in and lay particular emphasis on aligning our investment objectives to fellow investors’ investment interests. We always reserve capital for future capital raises and do not do investments in which we cannot. We invest in companies where it is possible for a private investor or venture syndicate to finance the R&D program all the way to regulatory approval. Therapeutic area focus All modalities and therapeutic areas are in scope as long as the biotech company is developing a novel medicine. Out of scope are investments that are, in our judgment, incremental innovation or a pureplay regulatory or pricing story. Medical devices, digital health and diagnostics companies are out of scope. Stage of company We invest in about-to-be clinical and clinical stage companies where the investment will result in a clinical readout for the lead asset. We can invest in any private financing round irrespective of whether its termed Series A, B, C or Cross-over Platform companies are also attractive, as long as the lead asset will get to a clinical readout with the financing. Geographic footprint We invest in companies in Europe and United States. We lay particular emphasis in investing in companies with Scandinavian roots, like our Firm has, and often start and build companies in Swedish and Danish ecosystem. Diseases afflicting people does not recognize geographic boundaries, science is global, financial capital is globally distributed and human capital is globally mobile. Therefore, we believe companies need to be built with that global perspective in mind. Our Core Values DECENT We show respect at all times We act with integrity and always aim to do the right thing Being reasonable builds long-term relationships DEDICATED We work hard to deliver results for patients, our companies and our LPs We are highly professional We love what we do CONFIDENT Our combined experience is extensive – we have been there before We trust our capabilities We are supported by a strong and extensive network HUMBLE We know our limitations We know when to listen and when to ask questions We are responsible stewards of our LP’s capital

HealthCap is a European venture capital firm investing exclusively and globally in life sciences. The investment strategy focuses on diseases with high unmet medical needs and breakthrough therapies that have the potential to be transformative and change medical practice, and the lives of patients suffering these conditions. Having raised more than EUR 1.2 billion since 1996, HealthCap has backed and built more than 125 companies, taken more than 45 companies public and done numerous trade sales. Over the years, HealthCap companies have developed more than 25 pharmaceutical products to market approval, many of which are breakthrough therapies helping patients with life-threatening diseases. In addition, HealthCap companies have brought more than 50 innovative medical device products to market. These products have generated significant value to many stakeholders, including patients, physicians and society, and as a result also to HealthCap investors.